• Explore /
  • Poster
  • / TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).

TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).

Abstract Poster

Authors

Rachel Freedman

Rachel A. Freedman

Dana-Farber Cancer Institute, Boston, MA

Rachel A. Freedman , Rebecca Sue Gelman , Jeffrey Scott Wefel , Ian E. Krop , Michelle E. Melisko , Alarice Lowe , Nathalie Agar , Kimberly L. Blackwell , Roisin M. Connolly , Polly Ann Niravath , Catherine H. Van Poznak , Shannon Puhalla , Nicole Ryabin , Elizabeth S Lawler , Nuhad K. Ibrahim , Minetta C. Liu , Antonio C. Wolff , Eric P. Winer , Nancy U. Lin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Breast Cancer - HER2/ER

Track

Breast Cancer

Sub Track

HER2+

Clinical Trial Registration Number

NCT01494662

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 528)

DOI

10.1200/jco.2014.32.15_suppl.528

Abstract #

528

Poster Bd #

18

Abstract Disclosures

Similar Posters

First Author: Min Yan

First Author: Carlos Hernando Barcenas

First Author: Ahmad Awada

First Author: Gavin M. Marx